Federated Hermes’s Stemline Therapeutics, Inc. STML Stock Holding History

Federated Hermes’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-196	Closed	-$3K	–	2339
2019 Q2	$3K	Buy	+196	New	+$2.83K	﹤0.01%	2063
2018 Q4	–	Sell	-105	Closed	-$2K	–	2371
2018 Q3	$2K	Buy	+105	New	+$1.68K	﹤0.01%	2171
2017 Q1	–	Sell	-400	Closed	-$4K	–	2218
2016 Q4	$4K	Sell	400 -81	-17%	-$980	﹤0.01%	1976
2016 Q3	$5K	Buy	+481	New	+$3.91K	﹤0.01%	1931

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes's STML Position: Q3 2019 in Review

Federated Hermes sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 196 shares — an estimated $3K sold.

Federated Hermes first reported a position in STML in Q3 2016 and held it in 4 quarters. The position peaked at $5K in Q3 2016. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

Federated Hermes reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Federated Hermes sold 196 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $3K.
Federated Hermes first reported a position in Stemline Therapeutics, Inc. in Q3 2016 and held it in 4 quarters.
Federated Hermes's Stemline Therapeutics, Inc. position peaked at $5K in Q3 2016.
100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Federated Hermes's 13F filing for Q3 2019, filed 14 Nov 2019.